San Francisco-based Audentes Therapeutics Inc. has closed a $30-million Series A financing round led by OrbiMed Advisors and including 5AM Ventures and Versant Ventures. The proceeds will reportedly be used to advance the company’s two lead programs, AT001 for X-linked myotubular myopathy, an inherited disorder characterized by severe muscle weakness and respiratory impairment affecting some 1 in 50,000 newborn males worldwide, and AT002 for Pompe disease, a rare, inherited disorder caused by gene mutations and manifesting in progressive muscle weakness and respiratory impairment affecting 1 in every 40,000 births. These treatments are apparently based on adeno-associated virus gene therapy technology. According to Audentes President and CEO Matthew Peterson, “This financing is a tremendous step forward for the development of new potential treatments for patients affected by very serious orphan muscle diseases.” See Audentes Therapeutics Inc. Press Release, July 18, 2013.